ERA-NET (European Research Area)

TRANSCAN-2 is funded by the EU’s Horizon 2020 Research and Innovation Programme. Grant Agreement No 643638.

01/01/2015 – 31/12/2020 (6 years)

Italian Ministry of Health


Fonds Zur Förderung der Wissenschaftlichen Forschung

Istituto Superiore di Sanità

Latvijas Zinatnu Akademija

Institut National du Cancer GIP

Bundesministerium Fuer Bildung Und Forschung

Deutsches Zentrum Fuer Luft – Und Raumfahrt Ev

Fondation Arc pour la Recherche sur le Cancer

Geniki Grammatia Erevnas Kai Technologias

Israeli Ministry of Health

Alleanza Contro Il Cancro

Zorgonderzoek Nederland Zon

Stichting Koningin Wilhelmina Fonds Voor De Nederlandse Kankerbestrijding

Norges Forskningsrad

Fundação para a Ciência e Tecnologia

Slovenska Akademia Vied

Ministrstvo Za Izobrazevanje, Znanost In Sport

Instituto de Salud Carlos III

Turkiye Bilimsel Ve Teknolojik Arastirma Kurumu

Narodowe Centrum Badan I Rozwoju

Fonds voor Wetenschappelijk Onderzoek-Vlaanderen

Orszagos Onkologiai Intezet


Federaal Fonds voor Wetenschappelijk Onderzoek

Ministero Dell’istruzione, Dell’università E Della Ricerca

Sihtasutus Eesti Teadusagentuur

Fundación para el Fomento en Asturias de la Investigación Científica Aplicada y la Tecnología

Taiwanese Ministry of Science and Technology

Valsts Izglitibas Attistibas Agentura

Vall d’Hebron Institute of Oncology

Why it matters

Cancer is a worldwide health burden and represents a major public health challenge in Europe. Today, an estimated 9 million individuals in Europe live with cancer, contributing to the ongoing increase in medical expenditures, and accordingly posing a major socio-economic challenge for the EU. Translational research applies knowledge from basic biology and clinical trials to techniques and tools that address critical medical needs to reduce cancer incidence and mortality rates and improve the quality of life of patients and overall health outcomes. TRANSCAN-2 aligns national and regional translational cancer research programmes and activities to link translational cancer research funding programmes. This avoids duplication of efforts and ensures more efficient use of available resources.

What ECPC does

ECPC sits on the project’s Scientific Advisory Board to ensure the project activities are in line with the needs of cancer patients, actively participating in discussions with ministries, funding agencies and research councils on translational cancer research programmes, and extending the cooperation through the exchange of information, harmonisation of funding mechanisms and assessment of results from the research projects funded.

EU flag logo

This project is funded by the European Union